Innovus Pharmaceuticals, Inc.,, an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men s and women's health and respiratory diseases, announced today that the Company has acquired four branded topical products from Boston Topicals, LLC, expanding
Steele Clarke Smith III is chairman and CEO of C3 International, a post-proof of concept, pre-revenue life sciences company specializing in cannabinoid therapeutics. C3's pioneering patient, a 21- year-old San Diego man, came monthly from San Diego for raw cannabis and capsules prepared for him, Smith said. As part of a wider DEA operation in South
*Promacta is the first new treatment in decades for newly diagnosed SAA patients in the US; a decision by the European Medicines Agency is expected in 2019. "Severe aplastic anemia can be a fatal diagnosis if left untreated, and many patients fail to respond to current initial treatment options," said Liz Barrett, CEO, Novartis Oncology. The FDA's
The report on "Active Pharmaceutical Ingredients Market" helps you to understand the market size, share, growth, trends, major companies performance data and market opportunities. Active Pharmaceutical Ingredients market and its meteoric rise from 2010. Ever-rising war between man and diseases has seen an upward rise in the recent years.
Nov. 16 Economic development officials gave tacit approval Thursday to transfer a $200 million industrial revenue bond for Augusta's Elanco animal pharmaceuticals plant to its new Brazil- based owner. The Augusta Economic Development Authority board voted to transfer Elanco's tax-exempt bonds to Union Agener, the U.S. subsidiary of a Sao Paulo- b
Novartis announced today that the US Food and Drug Administration has expanded the label for Promacta to include first-line treatment for adults and pediatric patients two years and older with SAA in combination with standard immunosuppressive therapy. "Severe aplastic anemia can be a fatal diagnosis if left untreated, and many patients fail
The Food and Drug Administration issued a notice in the Federal Register by Associate Commissioner for Policy Leslie Kux entitled "Request for Nominations for Individuals and Consumer Organizations for Advisory Committees". A summary of the notice, published in the Federal Register on Nov. 16, states: The Food and Drug Administration is requesting
FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication. Novartis International AG/ FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication. Processed and transmitted by West Corporation.
Novartis International AG/ Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/ HER2- locally advanced or metastatic breast cancer. Processed and transmitted by West Corporation. "Today's CHMP opinion brings us one step closer to providing more women with HR+/ HER2- advanced breast cancer in Europ
Agency: " Food and Drug Administration, HHS." ADDRESSES: All statements of interest from consumer organizations interested in participating in the selection process should be submitted electronically to ACOMSSubmissions@fda.hhs.gov, by mail to Advisory Committee Oversight and Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver Sp
The Food and Drug Administration has launched a new mobile app for capturing real-world data from patients to inform and assist clinicians in making regulatory decisions. Partnering with Kaiser Permanente on a pilot study, the FDA evaluated the functionality and engagement of its MyStudies app. It is expected that the MyStudies app will aid researc
Monday evenings at 63 Jefferson Ave., Salem; and from noon to 1:30 p.m. Fridays at 75 Lindall St., Danvers. The Beverly and Addison Gilbert Hospital's Speakers Bureau is a free service designed to bring timely information on a variety of health-related topics. Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at
Bayer and the National Consumers League release white paper that explores the risks consumers face when purchasing erectile dysfunction medicines from illegal online pharmacies and provides policy recommendations for increasing safe access to ED medicines. Bayer and the National Consumers League today released a white paper, Increased Consumer Risk
Mitsubishi Tanabe Pharma America, Inc. today announced that Mitsubishi Tanabe Pharma group companies will present pharmacokinetic data on an investigational oral suspension formulation of edaravone for the treatment of amyotrophic lateral sclerosis at the 29 th International Symposium on ALS/MND being held December 7-9 in Glasgow, Scotland.
"\"Nasal Spray\ "" Global Nasal Spray Market is expected to reach a CAGR of 6.3% in the forecast period 2018 to 2025. ADAPT Pharma, Inc., Sandoz International GmbH, INNOVUS PHARMACEUTICALS, INC., Cipla Inc., Aurena, J Pharmaceuticals, Bayer AG, St. Renatus, ARIUS FORMULATIONS PVT LTD, Ultratech India Limited, GlaxoSmithKline plc, Egalet Corporation
BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, is currently developing a personalized immunotherapy drug to treat advanced breast cancer. A recent article further discussing the company reads, Based on its research results, the company is developing a second immunotherapy
Santen Inc., a U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, today announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Developmen
AbbVie, a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of elagolix in women with uterine fibroids. These results were presented at the 47 th American...
Bayer and the National Consumers League today released a white paper, Increased Consumer Risk from Erectile Dysfunction Medication Advertised and Sold on the Gray Market, which exposes the dangers to consumers who purchase ED medication from illegal online pharmacies also known as the gray market. The white paper was commissioned by Bayer, and
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women s health and respiratory diseases, announced today its reported results for the third quarter 2018.. Revenues of approximately $7.4 mill
Innovus Pharmaceuticals, Inc., together with its subsidiaries, are collectively referred to as "Innovus", the "Company", "us", "we", or "our". The following information should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this report. For additional context with which to underst
Headquartered in Arden Hills, Minnesota, IntriCon Corporation is an international company engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. In addition to its operations in Minnesota, the Company has facilities in Illinois, Singapore, Indonesia, Germany and the United Kingdom. The Company sold the card
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update. Cumberland has a portfolio of eight U.S. Food and Drug Administration approved brands. "Our team has been very busy during the
Nov. 13 A Plymouth biopharmaceutical company, DiaMedica Therapeutics Inc., is proposing a stock offering to raise $15 million for the development and commercialization of a new drug to treat neurological and kidney diseases. "We have made significant progress in positioning DM199 to treat patients with stroke and kidney diseases," said Rick Paul